Impax Says Pfizer's Detrol Patent Suit Is Baseless
By Ben James ( March 6, 2008, 12:00 AM EST) -- Impax Laboratories Inc. President and Chief Executive Larry Hsu has alleged that Pfizer Inc.'s recent patent suit against Impax over urinary incontinence treatment Detrol LA is a ploy to fend off generic competition in the $857 million annual U.S. market for the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.